Not FDA-approved

Hormones & metabolism

Ipamorelin

Evidence

Early trials only

Class

Growth hormone secretagogue

/

Ipamorelin

KEY TAKEAWAY

Ipamorelin is a selective growth hormone secretagogue. It raises growth hormone in healthy volunteers but has no approved use, and a phase 2 trial for post-surgery recovery did not lead to approval.

Written by the Veylo editorial team · Updated

November 2026

At a glance

At a glance

What it is

A synthetic ghrelin receptor agonist

Studied for

Growth hormone stimulation and post-surgery bowel recovery

Key fact

Raises growth hormone levels; clinical benefit not established

Route

Injection (research use)

Evidence strength

Early trials only

What it is

What it is

Ipamorelin is a five-amino-acid peptide that mimics ghrelin at the growth hormone secretagogue receptor.

How it works

How it works

It prompts the pituitary to release growth hormone in pulses without strongly raising cortisol or prolactin in early studies.

Regulatory status

Regulatory status

Ipamorelin is not approved by the FDA and is not an approved treatment for any condition.

What it is used for

What it is used for

Studied for growth hormone deficiency and post-operative ileus. It has no approved medical use.

Side effects and risks

Side effects and risks

Headache, flushing and dizziness have been reported. Long-term effects of raising growth hormone are not well studied.

Citations

Citations

Primary literature for this entry is being compiled.

Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.

Veylo

Clinician-guided peptide care, paired with baseline blood testing and ongoing support.

Peptides referenced on this site are compounded medications and are investigational; they have not been approved by the FDA for the uses described. Nothing here is medical advice. Prescriptions are issued only after a licensed clinician reviews your history.

© 2026 Veylo. All rights reserved.

Veylo

Veylo

Veylo